Abstract
Introduction: ischemic stroke (IS) is the second leading cause of death in Colombia. The costs associated with IS were estimated to reach COP 5 billion during 2019.
Objective: To describe the direct medical costs of patients suffering from IS in an institution in Bogotá during 2020.
Methodology: a cross-sectional study analyzing the direct medical costs of hospital care for adults who experienced IS during 2020. Costs, length of stay, and clinical outcomes of patients who received thrombolysis were compared to those who did not.
Results: direct costs related to 132 IS patients were COP 1,218,970,831 in 2020 at our institution. The average price per patient was COP 7,845,073. Among hospital events, diagnostic imaging and other diagnostic methods represented the highest proportion of costs (40?%), with head and neck angiography standing out. IS severity significantly influenced total costs (p?=?0.018), as well as medication costs (p?<?0.001), procedures (p?<?0.001), and hospital stay (p?<?0.029). Thrombolysis patients were 1.33 times more costly than those with medical management (p?<?0.001), without significantly affecting the length of stay or mortality rate. Tracheitis (p?<?0.001) and gastrostomy (p?=?0.007) were associated complications that increased both costs and hospital stay.
Conclusion: intravenous thrombolysis in IS involves a significant increase in direct costs but reduces the burden of disability in treated patients. Costs increase with the severity of IS and the performance of specific additional procedures.
References
Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, et al. World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. Int J Stroke. 2022;17(1):18-29. https://doi.org/10.1177/17474930211065917
GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459-80. https://doi.org/10.1016/S1474-4422(18)30499-X
Gorelick PB. The global burden of stroke: persistent and disabling. Lancet Neurol. 2019;18(5):417-8. https://doi.org/10.1016/S1474-4422(19)30030-4
Martinez-Betancur O, Quintero-Cusguen P, Mayor-Agredo L. [Estimating disability-adjusted life-years for subtypes of acute ischemic stroke]. Rev Salud Publica (Bogota). 2016;18(2):226-37. https://doi.org/10.15446/rsap.v18n2.31692
MinSalud. Análisis de Situación de Salud (ASIS). Ministerio de Salud y Protección Social (Colombia); 2021. Disponible en: http://www.saludcapital.gov.co/DSP/Diagnsticos%20distritales%20y%20locales/Local/2017/Subred%20Norte/SUBRED%20NORTE.pdf.
Mendoza-Sánchez JA SF, Rangel-Celis LM, Arias JE, Zúñiga-Sierra EA. Modelo de costos asociados al ataque cerebrovascular y los eventos adversos en pacientes con fibrilación auricular no valvular tratados con warfarina. Rev Colomb Cardiol. 2019;26(3):125-32. https://doi.org/10.1016/j.rccar.2018.12.003
Moreno EA SK, Parada L, Zuluaga J, Bayona H. Análisis de costos de la atención hospitalaria en un paciente con fibrilación auricular no valvular y accidente cerebrovascular a repetición. Acta Neurol Colomb. 2022;38(3). https://doi.org/10.22379/24224022419
Hernández J, Salgado Flórez M. Costos directos de atención de accidentes cerebrovasculares en una empresa promotora de salud en el periodo 2015-2018. Cartagena: Universidad de Cartagena; 2020.
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 Guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344-418. https://doi.org/10.1161/STR.0000000000000211
Collazos MM GÁ, Londoño D, Bayona H, Herrán S, Pérez GE. Uso del activador de plasminógeno tisular recombinante (rt-PA) en el ataque cerebrovascular isquemico (ACVi) en Colombia: un estudio de costo efectividad. Acta Neurol Colomb. 2008;24(4):158-73.
García C, Martínez A, García V, Ricarute-Fajardo A, Torres I, Coral J. Actualización en diagnóstico y tratamiento del ataque cerebrovascular isquémico agudo. Universitas Medica. 2019;60(3). https://doi.org/10.11144/Javeriana.umed60-3.actu
Consultorsalud. Manual Tarifario SOAT de Salud 2020 2020. Disponible en: https://consultorsalud.com/wp-content/uploads/2020/01/Manual-Tarifario-SOAT-de-Salud-2020-Consultorsalud.pdf
ExchangeRates. Colombian Peso to US Dollar Spot Exchange Rates for 2020 2020. Disponible en: https://www.exchangerates.org.uk/COP-USD-spot-exchange-rates-history-2020.html
CCEMG - EPPI-Centre Cost Converter. 2019. Disponible en: http://eppi.ioe.ac.uk/costconversion/default.aspx
Strilciuc S, Grad DA, Radu C, Chira D, Stan A, Ungureanu M, et al. The economic burden of stroke: a systematic review of cost of illness studies. J Med Life. 2021;14(5):606-19. https://doi.org/10.25122/jml-2021-0361
Cha YJ. The economic burden of stroke based on South Korea's national health insurance claims database. Int J Health Policy Manag. 2018;7(10):904-9. https://doi.org/10.15171/ijhpm.2018.42
Abdo RR, Abboud HM, Salameh PG, Jomaa NA, Rizk RG, Hosseini HH. Direct medical cost of hospitalization for acute stroke in Lebanon: a prospective incidence-based multicenter cost-of-illness study. Inquiry. 2018;55:46958018792975. https://doi.org/10.1177/0046958018792975
Safanelli J, Vieira L, Araujo T, Manchope LFS, Kuhlhoff MHR, Nagel V, et al. The cost of stroke in a public hospital in Brazil: a one-year prospective study. Arq Neuropsiquiatr. 2019;77(6):404-11. https://doi.org/10.1590/0004-282x20190059
Icagasioglu A, Baklacioglu HS, Mesci E, Yumusakhuylu Y, Murat S, Mesci N. Economic burden of stroke. Turk J Phys Med Rehabil. 2017;63(2):155-9. https://doi.org/10.5606/tftrd.2017.183
Brinjikji W, Rabinstein AA, Cloft HJ. Hospitalization costs for acute ischemic stroke patients treated with intravenous thrombolysis in the United States are substantially higher than medicare payments. Stroke. 2012;43(4):1131-3. https://doi.org/10.1161/STROKEAHA.111.636142
Wentworth DA, Atkinson RP. Implementation of an acute stroke program decreases hospitalization costs and length of stay. Stroke. 1996;27(6):1040-3. https://doi.org/10.1161/01.STR.27.6.1040
Ehlers L, Andersen G, Clausen LB, Bech M, Kjolby M. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke. 2007;38(1):85-9. https://doi.org/10.1161/01.STR.0000251790.19419.a8
van Wijngaarden JD, Dirks M, Huijsman R, Niessen LW, Fabbricotti IN, Dippel DW, et al. Hospital rates of thrombolysis for acute ischemic stroke: the influence of organizational culture. Stroke. 2009;40(10):3390-2. https://doi.org/10.1161/STROKEAHA.109.559492
Hoffmeister L, Lavados PM, Mar J, Comas M, Arrospide A, Castells X. Minimum intravenous thrombolysis utilization rates in acute ischemic stroke to achieve population effects on disability: A discrete-event simulation model. J Neurol Sci. 2016;365:59-64. https://doi.org/10.1016/j.jns.2016.04.005
Gajurel BP, Nepal G, Jaiswal V, Ang SP, Nain P, Shama N, et al. Utilization rates of intravenous thrombolysis for acute ischemic stroke in Asian countries:: A systematic review and meta-analysis. Medicine (Baltimore). 2023;102(42):e35560. https://doi.org/10.1097/MD.0000000000035560
Masiliunas R, Vilionskis A, Bornstein NM, Rastenyte D, Jatuzis D. The impact of a comprehensive national policy on improving acute stroke patient care in Lithuania. Eur Stroke J. 2022;7(2):134-42. https://doi.org/10.1177/23969873221089158
Ouriques Martins SC, Sacks C, Hacke W, Brainin M, de Assis Figueiredo F, Marques Pontes-Neto O, et al. Priorities to reduce the burden of stroke in Latin American countries. Lancet Neurol. 2019;18(7):674-83. https://doi.org/10.1016/S1474-4422(19)30068-7
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.